Sun Pharma inks pact with Philogen for under-development cancer product

30 May 2023 , 03:14 PM

Sun Pharmaceutical Industries and Philogen SpA have entered into a licensing agreement to commercialize Nidlegy (Daromun), a specialty cancer product developed by Philogen, in Europe, New Zealand, and Australia.

Currently, Nidlegy is in advanced Phase III clinical trials. Nidelgy is a new immunotherapy product, which is said to cure melanoma and non-melanoma skin cancers and is currently being developed by Philogen.

As per the terms of agreement, Sun Pharma will have exclusive rights to commercialize Nidlegy for indications of skin cancer in Australia, Europe, and New Zealand.

As per a  a joint statement from the companies, Philogen will be responsible for completing pivotal clinical trials for the product in Europe. It will also pursue Marketing Authorization with regulatory authorities, and manufacture commercial supplies.

The statement further highlighted that Sun Pharma will look after commercialization activities, and both companies will equally share post-commercialization economies.

Intellectual Property Rights for Nidelgy will be retained by Philogen for other territories and indications other than skin cancers.

At around 3.06 PM, Sun Pharma was trading 1.08% lower at Rs 958 apiece, against the previous close of Rs 968.45 on NSE.

For feedback and suggestions, write to us at [e-mail]